Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board
Hikma Pharmaceuticals names former Cipla CEO Umang Vohra to its Board and Audit Committee.


Hikma Pharmaceuticals has appointed Umang Vohra as an independent Non-Executive Director, effective December 1, 2026. He will also join the company's Audit Committee and Nomination and Governance Committee from the same date, bringing experience across pharmaceutical manufacturing, business operations, finance and corporate leadership.
Vohra currently serves as Chair and CEO of Cohance Lifesciences, an India-listed, innovation-led contract development and manufacturing organisation (CDMO). He also holds an independent board position at AGS Health, an India-registered revenue cycle management company, and divides his professional responsibilities between the United States and India.
Commenting on the appointment, Victoria Hull, Chair, said, “I am delighted to welcome Umang to the Hikma Board. Umang is an experienced CEO with deep knowledge of the generic pharmaceutical market and an impressive track record in growth, innovation, portfolio development and transformation. His extensive international experience, particularly in North America, will bring valuable perspective to the Board.”
Previously, Vohra served as CEO of Cipla, where he led the company's transformation into a diversified global pharmaceutical enterprise. Earlier, he held senior finance, business development and operational positions at Dr Reddy's Laboratories, including Chief Financial Officer and Head of its North American business. His appointment adds extensive experience in the pharmaceutical industry and international business to Hikma's board.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas

Discussion